Biohaven expands at-the-market equity facility by $300M to total potential issuance

Biohaven Ltd.

Amendment No. 1 increases existing ATM capacity by $300M in common shares; sales via J.P. Morgan as manager.
New shares offered under effective shelf registration (333-274822) with prospectus supplement filed August 16, 2024.
Sales depend on market conditions, share price, and capital needs; timing and amounts are at company's discretion.
Original Equity Distribution Agreement dated October 2, 2023; prior capacity not disclosed in this filing.
Proceeds from any sales will be used for general corporate purposes as determined by management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.